
Pharmaron and Catapult Collaborate on CMC Strategies for Gene Therapy Development
On Wednesday, September 25th, Pharmaron and Catapult CGT co-hosted a Lunch and Learn event focused on “Successful CMC Strategies to Power Gene Therapy Development from Bench to Clinic.” Held at Catapult’s Skills and Training Laboratory, the session featured experts from Pharmaron’s Liverpool site, covering key topics in gene therapy and Chemistry, Manufacturing, and Controls (CMC).
Dr. Linda Randall, AVP of Manufacturing & Controls at Pharmaron Gene Therapy, delivered the keynote address, “The Power of Manufacturing Platforms to Accelerate IND-enabling Development.” Dr. Paul Young, Director of Process Sciences, and Kieron McIntyre, Associate Director of Biologics Development, presented on “Technology-Driven Innovations Addressing the Need for Speed and Quality” and “Analytical Method Validation and Beyond: A CMC Analytical Journey,” respectively.

Dr. Randall noted, “We had a full house at our Lunch and Learn at the Cell and Gene Therapy Catapult Centre in Stevenage. We thoroughly enjoyed sharing with them how we support drug developers in advancing their gene therapy products. The audience was highly engaged with many insightful questions during the session and had collaborative conversations after the networking.”
The event saw active participation from attendees, who engaged with the speakers and shared insights on gene therapy development.
For those who couldn’t attend, stay tuned for future events where we’ll continue to explore gene therapy strategies and innovations.